Jury Finds Pharma Supplier Didn't Misrepresent Origin of Glycine Later Found Chinese-Origin

A New Jersey U.S. District Court jury recently issued a not guilty verdict in a lawsuit alleging a glycine supplier intentionally misrepresented that glycine imported by Pharm-Rx was not of Chinese origin, when it was and ended up costing Pharm-Rx more than $700,000 in antidumping duties (see 1904020043). Following a six-day trial, the jury found that Pharm-Rx did not prove that BMP made any misrepresentation of country of origin that was likely to cause confusion as to the origin of the goods, nor did it make a material misstatement or omission of fact, or act in bad faith in performance of its contract with the importer, according to court documents. While the jury did find that BMP misrepresented or intentionally suppressed, concealed or omitted a “significant fact,” it found that Pharm-Rx’s reliance on that misrepresentation or intentional concealment was not justified. The court entered judgment in favor of BMP on Nov. 22.